MAGE-A4ᶜ¹º³²T for Multi-Tumor

ClinicalTrials.gov ID: NCT03132922

Public ClinicalTrials.gov record NCT03132922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.

Study identification

NCT ID: NCT03132922
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: USWM CT, LLC; Industry
Enrollment: 71 participants

Conditions and interventions

Conditions

Interventions

Genetic · Radiation

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 15, 2017 (Actual)
Primary completion: Dec 27, 2022 (Actual)
Completion: Sep 2032 (Estimated)
Last update posted: Jun 4, 2026

2017 – 2032

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Miami	Miami	Florida	33136	—
Moffitt Cancer Center	Tampa	Florida	33612	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Washington University	St Louis	Missouri	63112	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Duke University Medical Center, Duke Cancer Institute	Durham	North Carolina	27710	—
Ohio State University Wexner Medical Center	Columbus	Ohio	43210	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
Tennessee Oncology - Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
M.D. Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03132922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 4, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03132922 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →